Is it too soon to start reporting HER2 genetic heterogeneity?

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 2, 2010, Pages 162-163

  Albarracin, Constance ^a   Edgerton, Mary E ^a   Gilcrease, Michael Z ^a   Huo, Lei ^a   Krishnamurthy, Savitri ^a   Middleton, Lavinia P ^a   Resetkova, Erika ^a   Sahin, Aysegul A ^a   Sneige, Nour ^a   Symmans, W Frasher ^a   Wu, Yun ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN;

BREAST TUMOR; FEMALE; GENE AMPLIFICATION; GENETIC HETEROGENEITY; GENETICS; HUMAN; LETTER;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENETIC HETEROGENEITY; HUMANS; RECEPTOR, ERBB-2;

EID: 76449103424     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Vance GH, Barry TS, Bloom KJ, et al. Genetic Heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009;133(4):611-612.
2. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43.